<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940094</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5526A</org_study_id>
    <secondary_id>R01HL115041</secondary_id>
    <secondary_id>U54AR057319</secondary_id>
    <nct_id>NCT01940094</nct_id>
  </id_info>
  <brief_title>The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach</brief_title>
  <acronym>TAPIR</acronym>
  <official_title>The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center randomized controlled trial to evaluate the effects of using&#xD;
      low-dose prednisone as compared to stopping prednisone treatment entirely. Participants will&#xD;
      be randomized 1:1 to taper their prednisone dose down to 5 mg/day or to 0 mg/day for the&#xD;
      duration of the study (approximately six months) or until a study endpoint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with granulomatosis with polyangiitis (GPA, Wegener's) will be recruited at one of&#xD;
      the Vasculitis Centers of Excellence. Participants will be randomized 1:1 either to taper&#xD;
      their prednisone dose down to 5 mg/day according to a standardized schedule and stay at 5&#xD;
      mg/day of prednisone for the duration of the study or until a study endpoint, or taper their&#xD;
      prednisone dose down to 0 mg/day using a standard schedule and stay at 0 mg/day for the&#xD;
      duration of the study or until a study endpoint. All study participants will be followed for&#xD;
      6 months (from reaching a prednisone dose of 5 mg/day) or until an increase of prednisone&#xD;
      dose (after randomization) occurs, whichever comes first.&#xD;
&#xD;
      Participants will have up to four study visits, a screening visit (visit 1), a baseline&#xD;
      (visit 2), a month 3 visit (visit 3) and a month 6 or flare visit (visit 3) and up to two&#xD;
      follow-up phone calls from the study coordinator at randomization and at month 1&#xD;
      (randomization and 1 month phone call may be combined if randomization occurs at month 1).&#xD;
&#xD;
      This study is a project of the Vasculitis Clinical Research Consortium (VCRC) funded through&#xD;
      the National Institutes of Health Rare Diseases Clinical Research Network (RDCRN) with the&#xD;
      purpose of promoting vasculitis research. The VCRC is the major clinical research&#xD;
      infrastructure in North America for the study of vasculitis, and eight VCRC Centers of&#xD;
      Excellence will be recruiting for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physician decision to increase glucocorticoids for disease relapse.</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease flare.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes.</measure>
    <time_frame>6 months</time_frame>
    <description>Rate and type of serious adverse events and infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol performance at VCRC Centers of Excellence.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of patient characteristics, protocol compliance, participant retention, data completeness, timeliness of data entry, and data accuracy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life survey</measure>
    <time_frame>Measured at baseline and end of the study</time_frame>
    <description>Patient Reported Outcomes Measurement Information System (PROMIS) Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life surveys</measure>
    <time_frame>Measured at baseline and the end of the study</time_frame>
    <description>Measured by Short Form-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life surveys</measure>
    <time_frame>Measured at baseline, month 3, and end of the study</time_frame>
    <description>Measured by a Patient Global Assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Granulomatosis With Polyangiitis</condition>
  <arm_group>
    <arm_group_label>5 mg Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0 mg Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Prednisone</intervention_name>
    <description>Subjects will remain on daily prednisone dose of 5 mg</description>
    <arm_group_label>5 mg Prednisone</arm_group_label>
    <other_name>•5 mg/day glucocorticoids</other_name>
    <other_name>•5 mg/day prednisone</other_name>
    <other_name>•5 mg/day steroids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0 mg Prednisone</intervention_name>
    <description>Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day</description>
    <arm_group_label>0 mg Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Established diagnosis of granulomatosis with polyangiitis (GPA) where patients will&#xD;
             need to meet at least 2 of the 5 for the classification of GPA, at least one of which&#xD;
             must be criterion d or e:&#xD;
&#xD;
             The modified American College of Rheumatology (ACR) criteria are:&#xD;
&#xD;
             A. Nasal or oral inflammation, defined as the development of painful or painless oral&#xD;
             ulcers or purulent or bloody nasal discharge.&#xD;
&#xD;
             B. Abnormal chest radiograph, defined as the presence of nodules, fixed infiltrates,&#xD;
             or cavities.&#xD;
&#xD;
             C. Active urinary sediment, defined as microscopic hematuria (&gt;5 red blood cells per&#xD;
             high power field) or red blood cell casts.&#xD;
&#xD;
             D. Granulomatosis inflammation on biopsy, defined as histologic changes showing&#xD;
             granulomatous inflammation within the wall of an artery or in the perivascular or&#xD;
             extravascular area. Note: Pauci-immune glomerulonephritis seen on kidney biopsy will&#xD;
             suffice for this criterion.&#xD;
&#xD;
             E. Positive anti-neutrophil cytoplasmic antibody (ANCA) test specific for proteinase-3&#xD;
             measures by enzyme-linked immunoassay.&#xD;
&#xD;
             Patients who are myeloperoxidase (MPO) positive or ANCA negative are still eligible&#xD;
             for this study if they meet the criteria above and are felt to have GPA.&#xD;
&#xD;
          2. Active disease within the prior 12 months (initial presentation or relapse) that at&#xD;
             time of active disease required treatment with prednisone &gt;20 mg/day.&#xD;
&#xD;
          3. Disease remission at time of enrollment.&#xD;
&#xD;
          4. Prednisone dose at time of enrollment of ≥ 5 mg/day and ≤ 20 mg/day.&#xD;
&#xD;
          5. Participant age of 18 years or greater.&#xD;
&#xD;
          6. If the patient is taking an immunosuppressive medication agent other than prednisone&#xD;
             (maintenance agent) then the maintenance agent must be at a stable dose for one month&#xD;
             prior to enrollment with no plans by the treating physician to change the dose (other&#xD;
             than for safety purposes/toxicity) for the duration of the study (through the month 6&#xD;
             visit or early termination). Acceptable maintenance agents include azathioprine,&#xD;
             leflunomide, 6-mercaptopurine, methotrexate, mycophenolate mofetil, mycophenolate&#xD;
             sodium, or rituximab. Patients may be on trimethoprim/sulfamethoxazole (TMP/SMX) for&#xD;
             use as either a maintenance agent or for prophylaxis for infection. TMP/SMX may be&#xD;
             used in combination with other drugs.&#xD;
&#xD;
        6.1 If the patient is regularly taking trimethoprim/sulfamethoxazole at any dose then the&#xD;
        patient is eligible if there no plans by the treating physician to change the dose after&#xD;
        enrollment (other than dose reduction or discontinuation for safety purposes/toxicity) for&#xD;
        the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Comorbid condition that has moderate likelihood of requiring a course of prednisone&#xD;
        within one year of enrollment (e.g. chronic obstructive pulmonary disease (COPD), asthma,&#xD;
        adrenal insufficiency).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Merkel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffery P Krischer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol McAlear, MA</last_name>
    <email>cmcalear@upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Hughes</last_name>
      <email>Hughes.Samantha@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ulrich Specks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loretta Williams</last_name>
      <email>WILLIAL34@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Carol A Langford, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gillespie</last_name>
      <email>Sarah.Hopkins@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter A Merkel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica gonzalez</last_name>
      <email>jessica.gonzalez@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Curry Koening, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Messier</last_name>
      <email>smessier@stjosham.on.ca</email>
    </contact>
    <investigator>
      <last_name>Nader Khalidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneet Khurana</last_name>
      <email>Suneet.Khurana@sinaihealth.ca</email>
    </contact>
    <investigator>
      <last_name>Christian Pagnoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.org/cms/vcrc/</url>
    <description>Vasculitis Clinical Research Consortium</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 6, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Merkel</investigator_full_name>
    <investigator_title>Chief, Division of Rheumatology, Professor of Medicine and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Granulomatosis with polyangiitis</keyword>
  <keyword>Wegener's granulomatosis</keyword>
  <keyword>WG</keyword>
  <keyword>GPA</keyword>
  <keyword>ANCA-Associated Vasculitis</keyword>
  <keyword>AAV</keyword>
  <keyword>Vasculitis</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Glucocorticoid</keyword>
  <keyword>Taper</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

